[HTML][HTML] Evasion of the immune response by Trypanosoma cruzi during acute infection
MS Cardoso, JL Reis-Cunha… - Frontiers in …, 2016 - frontiersin.org
Trypanosoma cruzi is the etiologic agent of Chagas disease, a neglected tropical disease
that affects millions of people mainly in Latin America. To establish a life-long infection, T …
that affects millions of people mainly in Latin America. To establish a life-long infection, T …
Chagas disease diagnostic applications: present knowledge and future steps
V Balouz, F Agüero, CA Buscaglia - Advances in parasitology, 2017 - Elsevier
Chagas disease, caused by the protozoan Trypanosoma cruzi, is a lifelong and debilitating
illness of major significance throughout Latin America and an emergent threat to global …
illness of major significance throughout Latin America and an emergent threat to global …
Expanding an expanded genome: long-read sequencing of Trypanosoma cruzi
Although the genome of Trypanosoma cruzi, the causative agent of Chagas disease, was
first made available in 2005, with additional strains reported later, the intrinsic genome …
first made available in 2005, with additional strains reported later, the intrinsic genome …
Design, development and evaluation of rK28-based point-of-care tests for improving rapid diagnosis of visceral leishmaniasis
S Pattabhi, J Whittle, R Mohamath… - PLoS neglected …, 2010 - journals.plos.org
Background Visceral leishmaniasis (VL) is diagnosed by microscopic confirmation of the
parasite in bone marrow, spleen or lymph node aspirates. These procedures are unsuitable …
parasite in bone marrow, spleen or lymph node aspirates. These procedures are unsuitable …
Stage-specific proteomic expression patterns of the human filarial parasite Brugia malayi and its endosymbiont Wolbachia
S Bennuru, Z Meng, JMC Ribeiro… - Proceedings of the …, 2011 - National Acad Sciences
Global proteomic analyses of pathogens have thus far been limited to unicellular organisms
(eg, protozoa and bacteria). Proteomic analyses of most eukaryotic pathogens (eg …
(eg, protozoa and bacteria). Proteomic analyses of most eukaryotic pathogens (eg …
Immune complexes in chronic Chagas disease patients are formed by exovesicles from Trypanosoma cruzi carrying the conserved MASP N-terminal region
The exovesicles (EVs) are involved in pathologic host-parasite immune associations and
have been recently used as biomarkers for diagnosis of infectious diseases. The release of …
have been recently used as biomarkers for diagnosis of infectious diseases. The release of …
Comparison of Recombinant Trypanosoma cruzi Peptide Mixtures versus Multiepitope Chimeric Proteins as Sensitizing Antigens for Immunodiagnosis
C Camussone, V Gonzalez, MS Belluzo… - Clinical and Vaccine …, 2009 - Am Soc Microbiol
The aim of this work was to determine the best strategy to display antigens (Ags) on
immunochemical devices to improve test selectivity and sensitivity. We comparatively …
immunochemical devices to improve test selectivity and sensitivity. We comparatively …
Next-generation ELISA diagnostic assay for Chagas Disease based on the combination of short peptidic epitopes
J Mucci, SJ Carmona, R Volcovich… - PLoS neglected …, 2017 - journals.plos.org
Chagas Disease, caused by the protozoan Trypanosoma cruzi, is a major health and
economic problem in Latin America for which no vaccine or appropriate drugs for large …
economic problem in Latin America for which no vaccine or appropriate drugs for large …
Genetic and epigenetic mechanisms underlying cell-surface variability in protozoa and fungi
KJ Verstrepen, GR Fink - Annual review of genetics, 2009 - annualreviews.org
Eukaryotic microorganisms have evolved ingenious mechanisms to generate variability at
their cell surface, permitting differential adherence, rapid adaptation to changing …
their cell surface, permitting differential adherence, rapid adaptation to changing …
Insights into the immunological properties of intrinsically disordered malaria proteins using proteome scale predictions
Malaria remains a significant global health burden. The development of an effective malaria
vaccine remains as a major challenge with the potential to significantly reduce morbidity and …
vaccine remains as a major challenge with the potential to significantly reduce morbidity and …